Business Description
Prime Medicine is a Cambridge, Massachusetts-based biotechnology company founded in 2019 that develops gene editing treatments for a range of serious diseases. Its core technology, Prime Editing, allows scientists to make precise changes to DNA without cutting both strands, reducing the risk of unintended damage. The company has several programs in development, including a lead treatment for Chronic Granulomatous Disease currently in early clinical trials, as well as earlier-stage programs targeting Wilson Disease, a liver condition caused by a specific genetic mutation, and Cystic Fibrosis. Prime Medicine works alongside partners such as Bristol Myers Squibb, the Cystic Fibrosis Foundation, and the Broad Institute to advance its research.
